{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:55:57Z","timestamp":1787003757753,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06349-3","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T18:48:04Z","timestamp":1752691684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of factors influencing tumor volume doubling time in hepatocellular carcinoma and its predictive value for progression-free survival"],"prefix":"10.1038","volume":"15","author":[{"given":"Ting","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"issue":"12","key":"6349_CR1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal, A. G., Kanwal, F. & Llovet, J. M. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat. Rev. Clin. Oncol. 20 (12), 864\u2013884 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"6349_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000530495","volume":"12","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. Guidelines for the diagnosis and treatment of primary liver Cancer (2022 Edition). Liver Cancer. 12 (5), 405\u2013444 (2023).","journal-title":"Liver Cancer"},{"issue":"3","key":"6349_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3748\/wjg.v29.i3.413","volume":"29","author":"CR Criss","year":"2023","unstructured":"Criss, C. R. & Makary, M. S. Salvage locoregional therapies for recurrent hepatocellular carcinoma. World J. Gastroenterol. 29 (3), 413\u2013424 (2023).","journal-title":"World J. Gastroenterol."},{"key":"6349_CR4","doi-asserted-by":"publisher","first-page":"801981","DOI":"10.3389\/fpubh.2022.801981","volume":"10","author":"H Zou","year":"2022","unstructured":"Zou, H. et al. Economic burden and quality of life of hepatocellular carcinoma in greater china: A systematic review. Front. Public. Health. 10, 801981 (2022).","journal-title":"Front. Public. Health"},{"issue":"5","key":"6349_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1378\/chest.79.5.612b","volume":"79","author":"W Weiss","year":"1981","unstructured":"Weiss, W. Tumor doubling time. Chest 79 (5), 612\u2013613 (1981).","journal-title":"Chest"},{"issue":"13","key":"6349_CR6","doi-asserted-by":"publisher","first-page":"8480","DOI":"10.1245\/s10434-022-12368-5","volume":"29","author":"T Ramtohul","year":"2022","unstructured":"Ramtohul, T. et al. Tumor growth rate as a predictive marker for recurrence and survival after liver resection in patients with liver metastases of uveal melanoma. Ann. Surg. Oncol. 29 (13), 8480\u20138491 (2022).","journal-title":"Ann. Surg. Oncol."},{"issue":"10","key":"6349_CR7","doi-asserted-by":"publisher","first-page":"e1011507","DOI":"10.1371\/journal.pcbi.1011507","volume":"19","author":"A Sancho-Araiz","year":"2023","unstructured":"Sancho-Araiz, A. et al. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: the interplay between cancer cells and components of tumor microenvironment. PLoS Comput. Biol. 19 (10), e1011507 (2023).","journal-title":"PLoS Comput. Biol."},{"issue":"7","key":"6349_CR8","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s00330-009-1327-4","volume":"19","author":"M Mantatzis","year":"2009","unstructured":"Mantatzis, M. et al. Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate? Eur. Radiol. 19 (7), 1809\u20131816 (2009).","journal-title":"Eur. Radiol."},{"issue":"6","key":"6349_CR9","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.3390\/curroncol28060370","volume":"28","author":"SN Fuller","year":"2021","unstructured":"Fuller, S. N. et al. Tumor doubling time using CT volumetric segmentation in metastatic adrenocortical carcinoma. Curr. Oncol. 28 (6), 4357\u20134366 (2021).","journal-title":"Curr. Oncol."},{"issue":"1","key":"6349_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1148\/radiol.212426","volume":"304","author":"T Borde","year":"2022","unstructured":"Borde, T. et al. Optimization of the BCLC staging system for locoregional therapy for hepatocellular carcinoma by using quantitative tumor burden imaging biomarkers at MRI. Radiology. 304 (1), 228\u2013237 (2022).","journal-title":"Radiology"},{"issue":"10","key":"6349_CR11","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1007\/s10620-017-4708-6","volume":"62","author":"JK Kim","year":"2017","unstructured":"Kim, J. K. et al. Tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma. Dig. Dis. Sci. 62 (10), 2923\u20132931 (2017).","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"6349_CR12","first-page":"401","volume":"70","author":"P Nathani","year":"2021","unstructured":"Nathani, P. et al. Hepatocellular carcinoma tumor volume doubling time: A systematic review and meta-analysis. Gut 70 (2), 401\u2013407 (2021).","journal-title":"Gut"},{"issue":"4","key":"6349_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.hbpd.2021.02.005","volume":"20","author":"TM Gao","year":"2021","unstructured":"Gao, T. M. et al. The growth rate of hepatocellular carcinoma is different with different TNM stages at diagnosis. Hepatobiliary Pancreat. Dis. Int. 20 (4), 330\u2013336 (2021).","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"6349_CR14","doi-asserted-by":"crossref","unstructured":"Liu, C. C. et al. Prediction of surgical outcome by tumor volume doubling time via stereo imaging software in early non-small cell lung cancer. Cancers (Basel). 15(15). (2023).","DOI":"10.3390\/cancers15153952"},{"issue":"4","key":"6349_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3233\/CBM-210194","volume":"33","author":"J Perez-Morales","year":"2022","unstructured":"Perez-Morales, J. et al. Volume doubling time and radiomic features predict tumor behavior of screen-detected lung cancers. Cancer Biomark. 33 (4), 489\u2013501 (2022).","journal-title":"Cancer Biomark."},{"issue":"2","key":"6349_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3390\/curroncol29020038","volume":"29","author":"G Chen","year":"2022","unstructured":"Chen, G. et al. Prognostic significance of tumor growth rate (TGR) in patients with huge hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. Curr. Oncol. 29 (2), 423\u2013432 (2022).","journal-title":"Curr. Oncol."},{"issue":"6","key":"6349_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3892\/mco.2013.186","volume":"1","author":"N Shingaki","year":"2013","unstructured":"Shingaki, N. et al. Serological and histological indices of hepatocellular carcinoma and tumor volume doubling time. Mol. Clin. Oncol. 1 (6), 977\u2013981 (2013).","journal-title":"Mol. Clin. Oncol."},{"key":"6349_CR18","doi-asserted-by":"crossref","unstructured":"Glowska-Ciemny, J. et al. The role of Alpha-Fetoprotein (AFP) in contemporary oncology: the path from a diagnostic biomarker to an anticancer drug. Int. J. Mol. Sci. 24(3). (2023).","DOI":"10.3390\/ijms24032539"},{"issue":"10","key":"6349_CR19","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.3390\/curroncol29100593","volume":"29","author":"B Ruch","year":"2022","unstructured":"Ruch, B. et al. Hepatocellular carcinoma, alpha fetoprotein, and liver allocation for transplantation: past, present and future. Curr. Oncol. 29 (10), 7537\u20137551 (2022).","journal-title":"Curr. Oncol."},{"issue":"2","key":"6349_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3748\/wjg.v28.i2.216","volume":"28","author":"H Hanif","year":"2022","unstructured":"Hanif, H. et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J. Gastroenterol. 28 (2), 216\u2013229 (2022).","journal-title":"World J. Gastroenterol."},{"issue":"10","key":"6349_CR21","doi-asserted-by":"publisher","first-page":"e20850","DOI":"10.1016\/j.heliyon.2023.e20850","volume":"9","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Survival analysis and development of a prognostic nomogram for patients with hepatitis B virus-associated hepatocellular carcinoma. Heliyon 9 (10), e20850 (2023).","journal-title":"Heliyon"},{"issue":"5","key":"6349_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.6004\/jnccn.2021.7037","volume":"19","author":"EH Bent","year":"2021","unstructured":"Bent, E. H. et al. Integration of systemic and liver-directed therapies for locally advanced hepatocellular cancer: Harnessing potential synergy for new therapeutic horizons. J. Natl. Compr. Cancer Netw. 19 (5), 567\u2013576 (2021).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"6349_CR23","doi-asserted-by":"crossref","unstructured":"Minagawa, T. et al. Surgical and oncological outcomes of salvage hepatectomy for locally recurrent hepatocellular carcinoma after locoregional therapy: A Single-Institution experience. Cancers (Basel). 15(8). (2023).","DOI":"10.3390\/cancers15082320"},{"key":"6349_CR24","doi-asserted-by":"crossref","unstructured":"Huo, R. R. et al. Prognostic value of aspartate aminotransferase\/alanine aminotransferase ratio in hepatocellular carcinoma after hepatectomy. BJS Open.. 8(1). (2024).","DOI":"10.1093\/bjsopen\/zrad155"},{"key":"6349_CR25","doi-asserted-by":"crossref","unstructured":"Utsumi, M. et al. Predictive values of sarcopenia and systemic inflammation-based markers in advanced hepatocellular carcinoma after hepatectomy. Asian J. Surg. (2024).","DOI":"10.1016\/j.asjsur.2024.02.004"},{"key":"6349_CR26","doi-asserted-by":"crossref","unstructured":"Zeng, Z. X. et al. The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors. Hepatol. Int. (2023).","DOI":"10.1007\/s12072-023-10613-x"},{"key":"6349_CR27","doi-asserted-by":"crossref","unstructured":"Muhammed, A. et al. The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma. Cancers (Basel). 14(1). (2021).","DOI":"10.3390\/cancers14010186"},{"key":"6349_CR28","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/JHC.S411521","volume":"10","author":"J Zhou","year":"2023","unstructured":"Zhou, J. & Yang, D. Prognostic significance of hemoglobin, albumin, lymphocyte and platelet (HALP) score in hepatocellular carcinoma. J. Hepatocell Carcinoma. 10, 821\u2013831 (2023).","journal-title":"J. Hepatocell Carcinoma"},{"key":"6349_CR29","doi-asserted-by":"crossref","unstructured":"Nevola, R. et al. Gender differences in the pathogenesis and risk factors of hepatocellular carcinoma. Biology (Basel). 12(7). (2023).","DOI":"10.3390\/biology12070984"},{"issue":"3","key":"6349_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3350\/cmh.2015.21.3.279","volume":"21","author":"C An","year":"2015","unstructured":"An, C. et al. Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. Clin. Mol. Hepatol. 21 (3), 279\u2013286 (2015).","journal-title":"Clin. Mol. Hepatol."},{"key":"6349_CR31","doi-asserted-by":"crossref","unstructured":"Tan, D. et al. A Meta-Analysis on the rate of hepatocellular carcinoma recurrence after liver transplant and associations to etiology, Alpha-Fetoprotein, income and ethnicity. J. Clin. Med. 10(2). (2021).","DOI":"10.3390\/jcm10020238"},{"issue":"18","key":"6349_CR32","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.3748\/wjg.v26.i18.2221","volume":"26","author":"A Bohra","year":"2020","unstructured":"Bohra, A. et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care. World J. Gastroenterol. 26 (18), 2221\u20132231 (2020).","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"6349_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.4103\/jcrt.JCRT_651_20","volume":"17","author":"SM Zhao","year":"2021","unstructured":"Zhao, S. M. et al. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-gamma-carboxy prothrombin reactivity and modified response evaluation criteria in solid tumors. J. Cancer Res. Ther. 17 (3), 707\u2013714 (2021).","journal-title":"J. Cancer Res. Ther."},{"key":"6349_CR34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2147\/IJWH.S311419","volume":"13","author":"S Ratana-Amornpin","year":"2021","unstructured":"Ratana-Amornpin, S. et al. Clinical features and overall survival of females with hepatocellular carcinoma: A retrospective study and review of the literature in the association of Southeast Asian nations. Int. J. Womens Health. 13, 717\u2013725 (2021).","journal-title":"Int. J. Womens Health"},{"issue":"2","key":"6349_CR35","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/jgh.14816","volume":"35","author":"Y Purcell","year":"2020","unstructured":"Purcell, Y. et al. Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. J. Gastroenterol. Hepatol. 35 (2), 305\u2013313 (2020).","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06349-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06349-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06349-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:45:38Z","timestamp":1757249138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06349-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6349"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06349-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective study was approved by the Medical Ethics Committee of General Hospital of Ningxia Medical University (KYLL-2024-1350).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"25840"}}